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Graft-versus-host disease (GVHD) is a frequent life-threatening complication after allogeneic hematopoietic
stem cell transplantation (HSCT) and induced by donor-derived T cells that become activated by host antigen-
presenting cells. To address the relevance of host dendritic cell (DC) populations in this disease, we used
mouse strains deﬁcient in CD11cþ or CD8aþ DC populations in a model of acute GVHD where bone marrow
and T cells from BALB/c donors were transplanted into C57BL/6 hosts. Surprisingly, a strong increase in GVHD-
related mortality was observed in the absence of CD11cþ cells. Likewise, Batf3-deﬁcient (Batf3-/-) mice that
lack CD8aþ DCs also displayed a strongly increased GVHD-related mortality. In the absence of CD8aþ DCs, we
detected an increased activation of the remaining DC populations after HSCT, leading to an enhanced priming
of allogeneic T cells. Importantly, this was associated with reduced numbers of regulatory T cells and
transforming growth factor-b levels, indicating an aggravated failure of peripheral tolerance mechanisms
after HSCT in the absence of CD8aþ DCs. In summary, our results indicate a critical role of CD8aþ DCs as
important inducers of regulatory T cellemediated tolerance to control DC activation and T cell priming in the
initiation phase of GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
For patients with high-risk hematological malignancies,
allogeneic hematopoietic stem cell transplantation (HSCT)
is the only curative treatment option. The therapeutic ef-
ﬁcacy is based on the emergence of curative immune re-
sponses against residual malignant cells in the host induced
by donor lymphocytes [1]. Although effective for many
patients, undesired immune responses against otherwise
healthy tissues frequently occur after HSCT and cause graft-
versus-host disease (GVHD). Complications related to
GVHD are the most important contributors to the high
treatment-related morbidity and mortality rates post-HSCT
[2]. Therefore, a deeper understanding of the immunolog-
ical mechanisms that initiate and maintain GVHD isedgments on page 1703.
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ty for Blood and Marrow Transplantation.necessary to improve the feasibility and allow broader
application of this otherwise elegant immunological treat-
ment approach.
Acute GVHD is primarily caused by donor-derived T cells
within the allogeneic stem cell graft that become activated
after contact with host-derived antigen-presenting cells
(APCs) [3]. These primed allogeneic T cells successively as-
sault healthy tissues (eg, in the liver, gut, and skin), creating
GVHD [4]. Although dendritic cells (DCs) are highly potent in
Tcell priming in general [5] and also important in the context
of GVHD, there is considerable debate on the precise role of
DCs in the regulation of GVHD. On one hand, host-derived
DCs are sufﬁcient for the initiation of GVHD [6], but on the
other, donor-derived DCs may also contribute to the priming
of allogeneic T cells [7]. Beyond this, host-derived non-
hematopoietic cells may likewise be sufﬁcient to induce
GVHD [8,9]. Interestingly, depletion of speciﬁc DC subsets,
such as Langerhans cells [10] and conventional or plasma-
cytoid DC populations, does not prevent GVHD, illustrating
the complexity of T cell activation in this setting.
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central and peripheral tolerance [11], mostly regulated by
their activation state [12] and contact with regulatory T
(Treg) cells [13]. In particular, CD8aþ DCs are critical for CD8þ
T cell responses initiated by cross-priming [14] but,
conversely, may be also involved in the induction of toler-
ance [15]. With respect to GVHD, vaccination with host-type
CD8aþ DCs reduces GVHD [16], demonstrating the relevance
of CD8aþ DCs in the regulation of immune responses after
HSCT. Moreover, CD8aþ DCs play a role for the induction of
graft-versus-tumor (GVT) responses, as shown in a minor
histocompatibility antigen (miHA) mismatched HSCT model
[2,17]. Nevertheless, the direct role of CD8aþ DC in induction
of GVHD has only been incompletely deﬁned.
To elucidate the role of host-derived DCs in the initiation
of GVHD, we used 2 transgenic mouse strains deﬁcient of
CD11cþ DC populations in a mouse model of acute GVHD and
surprisingly found a strong increase in GVHD-related mor-
tality in the absence of CD11cþ cells. Because Batf3-deﬁcient
(Batf3-/-) mice are devoid of the CD8aþ DC subpopulation
under steady state conditions [14,18], we transplanted
Batf3-/- mice with bone marrow and T cells from MHC and
miHA mismatched BALB/c to directly address the role of
CD8aþ DCs in the initiation of GVHD, again resulting in a
strongly increased GVHD-related mortality. Interestingly, the
lack of this DC subset was accompanied with an increased
activation of the remaining DC populations post-HSCT,
leading to an enhanced priming of allogeneic T cells. More-
over, we found reduced numbers of Treg cells and trans-
forming growth factor (TGF)-b levels, suggesting an
aggravated failure of peripheral tolerance mechanisms after
HSCT in the absence of CD8aþ DCs. In summary, our results
indicate a role of CD8aþ DCs as important inducers of Treg
cellemediated tolerance that control DC activation and T cell
priming in GVHD.METHODS
Reagents
Anti-NK1.1 mAb (clone PK136) was puriﬁed from hybridoma superna-
tants according to standard protocols. If required, mAbs were afﬁnity puri-
ﬁed using protein G-Sepharose columns (GE Healthcare, Munich, Germany).Mice
C57BL/6 (B6) and BALB/c were obtained from Charles River Laboratories
(Sulzfeld, Germany). Batf3 deﬁcient (B6.129S(C)-Batf3tm1.1Kmm/J; Batf3-/-)
mice were from The Jackson Laboratory (Sulzfeld, Germany). Batf3-/- mice
were backcrossed for 10 generations with B6 and at least 1 ﬁlial generation
upon purchase. Filial breedings were continued at our center. All mice were
bred in a speciﬁc pathogen-free colony in the animal facility of the Johannes
Gutenberg-University. CD11c-Cre [19], DTA [20], and inducible diphtheria
toxin receptor (iDTR) [21] mice were from A. Waisman (Mainz) and bred as
previously described [22]. All animal procedures were performed in accor-
dance with the institutional guidelines and approved by the responsible
national authority (National Investigation Ofﬁce Rheinland-Pfalz, approval
ID AZ 23 177-07/G11-1-034).Bone Marrow Transplantation Model and Histopathology Scoring
Mice were transplanted following a standard protocol as previously
described [23]. B6 recipients were natural killer cell depleted with an anti-
NK1.1 speciﬁc antibody (clone PK136, 500 mg i.p. per mouse on day 2) and
received allogeneic T celledepleted bone marrow cells (107 cells per animal)
and 5  106 CD90.2þ T cells from BALB/c donors by i.v. transfer after total
body irradiation (TBI; 11 Gy split into 2 doses of 5.5 Gy on days 2 and 1)
from a 137Cs source (OB58-BA, Buchler, Braunschweig, Germany). The ani-
mals were maintained under speciﬁc pathogen-free conditions and received
antibiotics (sulfadoxine-trimethoprim 1 g/mL in drinking water) post-
transplantation. For in vivo DC depletion, CD11c-iDTR mice were injected
i.p. with 25 ng/g body weight diphtheria toxin (Sigma-Aldrich, Taufkirchen,
Germany) on days 2 and 1.Clinical symptoms of GVHD were monitored daily by assessing weight
loss, posture, activity, fur texture, and skin integrity, adding up to a clinical
GVHD score as previously described [24]. Animals with severe GVHD
deﬁned by clinical scores 6 were killed as required by the institutional
animal ethics guidelines and the day subsequent to death determined as the
following day.
Samples of large intestine, liver, and skin were taken on day 10 and
stained with H & E. The sections were reviewed and scored by one of the
authors (B.R.) who was blinded to the experimental groups according to a
previously published histopathology scoring system [11,25].
Flow Cytometry Staining and Analyses
All analyses were performed with an LSRII ﬂow cytometer and FACSDiva
(Becton Dickinson, Heidelberg, Germany) or FlowJo (Tree Star Inc, Ashland,
OR, USA) software. The following mAbs were used: CD3 (clone 145-2C11),
CD4 (clone GK1.5), CD8 (clone 53-6.7), CD11c (clone N418), MHC class II
(clone M5/114.15.2), CD45.2 (clone 104), CD80 (clone 16-10A1), CD86 (clone
GL1), CD90.2 (clone 53-2.1), CD229.1 (clone 30C7), PD-L1 (clone 10F.9G2),
PD-L2 (clone 122), and FoxP3 (clone FJK-16S) (all antibodies were purchased
from Biolegend, San Diego, CA, USA or eBioscience, Frankfurt, Germany).
Viability was determined by propidium iodide (Sigma-Aldrich). Total cell
counts in the spleen were determined by ﬂow cytometry using counting
beads (Beckmann-Coulter, Krefeld, Germany) according to the manufac-
turer’s instructions.
Cell Puriﬁcation and Culture
Splenic DCs were puriﬁed by digestion using DNase I (100 mg/mL;
Sigma-Aldrich) and collagenase type 2 (1 mg/mL; Worthington Biochemical
Corporation, Lakewood, NJ, USA) followed by density centrifugation as
described previously [12,23] and further enriched by using CD11c speciﬁc
magnetic microbeads according to the manufacturer’s protocol (Miltenyi
Biotech, Bergisch Gladbach, Germany). These cells were typically >95%
CD11cþ as determined by ﬂow cytometry.
For mixed lymphocyte reaction (MLR), spleens and mesenteric lymph
nodes (MLNs) were digested in DNase I (100 mg/mL; Sigma) and collagenase
type 2 (1mg/mL;Worthington Biochemical Corporation) and dissectedwith
needles, erythrocytes were lysed, and cells subsequently treated with
mitomycin C (60 mg/mL; Sigma) for 30 minutes to inhibit further cell divi-
sion. Responder T cells from BALB/c splenocytes were puriﬁed by anti-
CD90.2econjugated magnetic beads (Miltenyi Biotech). Puriﬁed T cells were
generally>95% positive for CD90 and CD3 as determined by ﬂow cytometry.
Stimulator and responder cells were cultured for 3 days, pulsed with 3H-
thymidine (0.5 mCi/mL; Perkin Elmer, Rodgau, Germany), and harvested the
following day. 3H-thymidine incorporation was assessed with a 1205 beta-
plate reader (LKB Wallac, Turku, Finland).
mRNA Detection
RNA was isolated using TRIzol (Invitrogen, Darmstadt, Germany), and
cDNA was synthesized with RevertAid M-MuLV reverse transcriptase
following the recommendations of the supplier (Fermentas, Thermo-
Scientiﬁc, Schwerte, Germany). Quantitative real-time (qRT)-PCRs were
performed using the following oligonucleotides: murine IL-10 forward 50-
GAGAGC GCT CAT CTC GAT TT-30; murine IL-10 reverse 50-GGG TCT CCC AAG
GAA AGG TA-30; b2-microglobulin forward 50-TTT CTG GTG CTT GTC TCA CTG
ACC G-30; b2-microglobulin reverse 50-GCA GTT CAG TAT GTT CGG CTT CCC
A-30; murine IL-12p35 forward 50-GTC AAT CAC GCT ACC TCC TC-30; murine
IL-12p35 reverse 50-CTG CAC AGC TCA TCG ATG GC-30; murine Ifng forward
5‘-GAT GCA TTC ACC AGG T-3‘; murine IFN-g reverse 50-GTG GAC CAC TGA
GCT C-30 . qRT-PCR analyses were performed in triplicates on an iCycler (Bio-
Rad, Munich, Germany) using the SYBR GreenER qPCR Supermix (Invi-
trogen). After normalization of the data according to the expression of
b2-microglobulin mRNA, the relative expression level of Ifng, Il-10, and
Il-12p35 mRNA was calculated.
Detection of IL-2 and TGF-b
Micewere killed on day 7 post-HSCT by CO2 asphyxiation and peripheral
blood taken by retro-orbital bleeding and centrifuged. Cell free serum
samples were frozen at 20C until required. IL-2 was detected by a speciﬁc
ELISA using anti-mIL-2 (JES6-1A12) and biotinylated anti-mIL-2 (JES6-5H4;
both from BD Biosciences, Heidelberg, Germany) as previously described
[26]. TGF-b ELISA (from R&D Systems, Wiesbaden, Germany) was used ac-
cording to the manufacturer’s instructions.
Statistical Analysis
Analyses were performed by a 2-tailed Student’s t-test for comparison
between 2 groups as indicated. Multiple groups were compared by 1-way
ANOVA with Bonferroni’s post-test. Survival analysis was performed by
the Mantel-Cox test. For all analyses, P < .05 was considered signiﬁcant. All
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Mac OS X, GraphPad Software, San Diego, CA, USA, www.graphpad.com).RESULTS
Host-Derived Conventional DCs Are Dispensable for the
Induction of Acute GVHD
To analyze the general role of conventional DCs in GVHD
induction, we used our previously described diphtheria toxin
A (Rosa-DTA) model [22] in which DCs are continuously
ablated when crossed to the CD11c-Cre line 21. We used a
well-established mouse model for HSCT, where C57BL/6 (B6)
or DC-deﬁcient CD11c-DTA recipients received a lethal dose
of TBI (11 Gy) and were transplanted with T celledepleted
bone marrow and puriﬁed T cells from MHC and miHA
mismatched BALB/c donors. Wild-type B6 animals devel-
oped clinical signs of acute GVHD as evidenced by weight
loss, decreased activity, and loss of fur (not shown), resulting
in a lethal course of disease in all animals with a median
survival of 28 days (Figure 1A). Unexpectedly, DC-deﬁcient
CD11c-DTA mice developed more severe signs of GVHD as
compared with controls, resulting in death of all trans-
planted CD11c-DTA recipients within a signiﬁcantly accel-
erated timeframe (median survival of 11 days, P < .001 by
Mantel Cox test).
Because the continuous ablation of DCs resulted in an
autoimmune disorder phenotype because of the lack of
control by Treg cells [27], we next used another model of
transient DC ablation in vivo. For this we used our previously
described iDTR model crossed to the CD11c-Cre line (CD11c-
iDTR) [22]. Depletion of DCs in these mice was achieved by
the injection of diphtheria toxin. As shown in Figure 1B,
when transplanting CD11c-iDTR recipients with or without
additional DC depletion by diphtheria toxin treatment, we
observed all mice that had received diphtheria toxin rapidly
died (median survival, 8 days), similar to the course of GVHD
in CD11c-DTA mice (Figure 1A). In contrast, CD11c-iDTR re-
cipients not receiving diphtheria toxin displayed a prolongedFigure 1. Enhanced GVHD-related mortality in the absence of conventional of CD8aþ
were lethally irradiated (11 Gy in split dose) and transplanted allogeneic T celledeple
BALB/c donor mice. Kaplan-Meier survival analysis of GVHD-related mortality of the i
mice received diphtheria toxin (25 ng/g, on days e2 and 1) for DC depletion. The resu
independent experiments with 5 to 8 mice per group. (D) HSCT was performed as in (C
were taken and sections were stained with H & E and histopathological scores (inﬂ
(P < .05) by Mantel-Cox test. **Statistical signiﬁcance (P < .05) by Student’s t-test.survival (median survival, 23 days, P < .001 by Mantel Cox
test), comparable with the course of GVHD in B6 recipients.
DCs are a heterogeneous population of cells, and distinct
DC subsets may exert diverse effects on the immune re-
sponses post-HSCT. Therefore, we decided to focus on 1
particular subset, namely CD8aþ DCs, that are a deﬁned
lineage depending on the AP1 transcription factor Batf3.
Hence, Batf3-/- mice constitutively lack the CD8aþ DC sub-
population [14]. As depicted in Figure 1C, the transplanted
wild-type B6 animals developed acute signs of illness, and
nearly all mice succumbed to GVHD (94%; median survival,
43 days), whereas Batf3-/- mice displayed a strongly aggra-
vated course of GVHD as illustrated by the 100% lethal
outcome and a median survival of 8 days (P < .001 by Mantel
Cox test). When comparing transplanted wild-type B6 and
Batf3-/- mice for histological evidence of GVHD (Figure 1D),
we detected increased signs of GVHD in the colon (P < .05 by
Student’s t-test) and in the liver, the latter not reaching sta-
tistical signiﬁcance (P ¼ .15 by Student’s t-test). In contrast,
we found decreased signs of GVHD in the skin as another
typical GVHD target organ (P < .05 by Student’s t-test), sug-
gesting a distinct role of CD8aþ DCs during GVHD in different
target organs.
Taken together, these results indicate in 3 distinct models
that host-derived conventional DCs are protective against
the adverse outcomes. Apparently, the organ-speciﬁc distri-
bution of DC subsets contributes to the pace and histopa-
thology phenotype of GVHD.
Rapid Depletion and Concurrent Activation of Host DCs
after HSCT
Allogeneic T cell priming occurs on contact of trans-
planted donor T cells with host APCs [28]. Because host-
derived DCs were not required for the induction of GVHD
and the TBI conditioning regimen rapidly depletes various
hematopoietic cell types, inducing apoptosis, including
DCs [29], we were interested in the depletion kinetics ofDCs. (A-C) Recipient mice (B6, CD11c-DTA, CD11c-iDTR or Batf3-/- as indicated)
ted bone marrow cells (5  106 cells) and CD90.2þ T cells (5  105 cells) from
ndicated treatment groups is shown. In (B) the indicated group of CD11c-iDTR
lts in (A) show a single experiment. The analyses in (B, C) are cumulated from 2
) except mice were killed on day 10. Samples from the intestine, liver, and skin
ammation, apoptosis) determined (n ¼ 7 per group). *Statistical signiﬁcance
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Therefore, we quantiﬁed the number of viable DCs (gating on
viable propidium iodideMHC IIþ CD11cþ cells) in the spleen
of transplanted B6mice (Figure 2A). As expected, the number
of DCs daily decreased by a factor of 2 until day 4 post-HSCT.
In line with previous reports [30], the remaining viable DCs
displayed an activated phenotype (Figure 2B).
Because Batf3-/- mice have residual CD8aþ DCs due to
Batf-dependent compensatorymechanisms that may expand
under inﬂammatory conditions [18], we examined the fate of
donor CD8aþ DCs after TBI in wild-type and Batf3-/- mice.
Under steady-state conditions, we detected a reduced fre-
quency of CD8aþ DCs in the spleen and MLNs that was
strongly reduced 24 hour after TBI (Figure 2C), suggesting
these compensatory mechanisms are unable to account the
aggravated course of GVHD we observed in Batf3-/- mice
since Tussiwand et al. [18] observed an expansion of CD8aþ
DCs in Batf3-/- mice in various inﬂammation models.Figure 2. Host DCs are activated but rapidly depleted after HSCT. Recipient B6 mi
T celledepleted bone marrow cells (5  106 cells) and CD90.2þ T cells (5  105 cells) f
indicated time points and stained for viable DCs (identiﬁed by propidium iodide C
calibrated counting beads. The cumulated results from 2 independent experiments a
histograms of splenic DCs (gated on propidium iodide CD11cþ MHC IIþ cells) for surfa
or 24 hours after HSCT (blue) are depicted. (C) Mice were left untreated (B6 or Batf3-
harvested 24 hours later and analyzed by ﬂow cytometry for CD8aþ DCs (gating on p
analysis of 2 independent experiments with 6 mice per group is shown. (D) Represen
CD11cþMHC IIþ cells) and shown after staining for the donor (BALB) speciﬁc marker C
DCs is indicated. *Signiﬁcant difference (P < .05) to the untreated control group by
(P < .05) between the indicated groups by Student’s t-test.To further investigate whether the DCs shown in
Figure 2Awere of host or donor origin, we used the congenic
surface marker CD229.1 (Ly9.1) expressed only in hemato-
poietic cells from BALB mice [31] and assessed the DC
chimerism in the spleen over time by ﬂow cytometry. Most
DCs were of host origin until day 3 post-HSCT (Figure 2D).
Although the absolute numbers of DCs were very low by day
4, it appears possible and consistent with previous data [30]
that a sufﬁcient number of host- or donor-derived DCs are
present during the initial phase of GVHD to inﬂuence the
course of GVHD.
CD8aþ DCs Suppress the TBI-Induced Activation of the
Remaining DC Subsets
Because we observed an aggravated course of GVHD in
the absence of host conventional DCs and conversely in the
absence of CD8aþ DCs, we were interested in the activation
phenotype of CD8aþ versus CD8a DC subsets after HSCT.ce were lethally irradiated (11 Gy in split dose) and transplanted allogeneic
rom BALB/c donor mice as described before. Splenocytes were harvested at the
D11cþ MHC IIþ cells). (A) The absolute number of DCs was determined using
re depicted (n ¼ 6 per time point). (B) Representative ﬂow cytometry overlay
ce expression of MHC II, CD80, and CD86, respectively, of untreated mice (red)
/-) or lethally irradiated (11 Gy in split dose) and spleens (left) and MLNs were
ropidium iodide CD3CD19- F4/80- and CD11cþ MHC IIþ cells). A cumulative
tative ﬂow cytometry histograms of splenic DCs (gated on propidium iodide
D229.1 at the indicated time points post HSCT. The percentage of donor-derived
1-way ANOVA and Bonferroni’s posttest comparison. **Signiﬁcant difference
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propidium iodide MHC IIþ CD11cþ cells) in the spleen and
MLNs for the activation phenotype inwild-type B6 or Batf3-/-
mice after TBI. In line with others [17,18], we detected no
CD8aþ DCs in Batf3-/- mice under steady-state conditions. In
contrast to splenic DCs (data not shown), in the MLNs the
surface expression patterns of MHC class II and the cos-
timulatory molecules CD80 and CD86 were comparable in
CD8aþ and CD8a DC populations in untreated wild-type
(B6) and Batf3-/- mice (Figure 3A). Consistent with the pre-
vious work by Zhang et al. [30] and Lin et al. [13], we
observed a strong up-regulation of MHC class II and cos-
timulatory molecules on DCs after TBI. Interestingly, this
TBI-induced activation phenotype was restricted to the
CD8a DC populations and signiﬁcantly attenuated in the
CD8aþ DC population in the wild-type B6 animals. Moreover,
although we did not observe any differences in the steady-
state DC phenotype of Batf3-/- mice, the expression levels of
MHC class II as well as CD86 and the related B7 family
molecules PD-L1 and PD-L2 were even increased in DCs from
Batf3-/- mice, suggesting a hyperactivated state in these an-
imals post-TBI. Further corroborating this ﬁnding, we
detected increased levels of Il-12p35, Il-10, and Ifng mRNA in
the MLNs of Batf3-/- mice after TBI compared with the
respective wild-type B6 controls (Figure 3B). Collectively,
these data indicate that CD8aþ DCs contribute to theFigure 3. Enhanced activation of conventional DCs in the absence of CD8aþ DCs after
dose as before; B6 post TBI or Batf3-/- post TBI) and MLNs were harvested 24 hours afte
CD11cþ MHC IIþ cells, indicated as “all”). DCs from B6 mice were further subdivided b
ﬂow cytometry. The expression levels MHC II and the activation markers CD80/CD
inhibitory B7 family molecules PD-L1 and PD-L2 were quantiﬁed on DCs (gating on p
from 1 representative of 3 independent experiments performed with 3 mice per gro
post-TBI (B6 or Batf3-/-). mRNA levels of Il12p35, Il10 and Ifng (mean plus SD) were a
used as housekeeping gene. Data shown are from 1 representative (n ¼ 3 mice per gro
indicated groups by 1-way ANOVA and Bonferroni’s post-test comparison. **Statistica
Student’s t-test compared with the untreated control (B6 or Batf3-/-).suppression of DC activation post-TBI and suggest the
aggravated course of GVHD in Batf3-/- mice may be mediated
by the enhanced allogeneic T cell activation in the absence of
CD8aþ DCs.
CD8aþ DCs Regulate Allogeneic MLR after TBI-
Conditioning Treatment
So far, our results described a more activated DC pheno-
type in the MLNs after TBI conditioning in Batf3-/- mice but
did not clarify whether this is related to the adverse outcome
of these animals. We hypothesized that this enhanced DC
activation more effectively triggers allogeneic T cell activa-
tion, resulting in an aggravated course of GVHD and early
death of Batf3-/- mice post-HSCT. To directly address this
question, we harvested MLNs from Batf3-/- mice or the
respective wild-type B6 control animals after TBI and used
these cells as stimulator APCs for naïve allogeneic Tcells from
BALB/c donors in an allogeneic MLR. As shown in Figure 4A
using MLN cells from untreated mice as stimulators, we only
observed a minor increase in T cell proliferation in the
presence of Batf3-/- cells compared with the wild-type B6
controls (P< .05 by paired Student’s t-test). In contrast, when
using MLN cells frommice 24 hours post-TBI conditioning as
stimulators, we observed a reduction of Tcell proliferation by
about 50% compared to thewild-type B6 controls (Figure 4B),
most likely due to a TBI-induced reduction of APC numbers.TBI. Mice were left untreated (B6 or Batf3-/-) or lethally irradiated (11 Gy in split
r TBI. (A) The cells were stained for viable DCs (identiﬁed by propidium iodide
y the surface expression of CD8a (indicated as CD8þ or CD8) and analyzed by
86 are quantiﬁed in the respective DC subsets. The expression levels of the
ropidium iodide CD11cþ MHC IIþ cells). The depicted data are mean and SD
up. (B) Total RNA was extracted from MLN cells of untreated mice or 24 hours
ssessed by real-time PCR and normalized to levels of untreated mice. B2m was
up) of 2 independent experiments. *Signiﬁcant difference (P < .05) between the
l signiﬁcance (P < .05) by Student’s t-test. #Statistical signiﬁcance (P < .05) by
Figure 4. Enhanced allogeneic MLR response in the absence of CD8aþ DCs after TBI. B6 (ﬁlled bars) or Batf3-/- (open bars) mice were left untreated (A) or lethally
irradiated (11 Gy in split dose as before; B6 post TBI or Batf3-/- post-TBI) (B). After 16 hours, the MLNs were isolated and used as stimulators for freshly isolated
allogeneic CD90.2þ T cells from BALB/c donors at the indicated ratios. T cell proliferation was quantiﬁed after pulsing with 3H-thymidine on day 3 and harvested
18 hours later. The depicted results are mean þ SD from 1 of 2 representative experiments each assayed in triplicate wells with 3 mice per group. *Ssigniﬁcant
difference (P < .05) by paired Student’s t-test.
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response induced by Batf3-/- MLN cells after TBI. Thus, the
absence of CD8aþ DCs not only leads to a more activated DC
phenotype after TBI but also induces an enhanced allogeneic
T cell response compatible with the aggravated course of
GVHD and increased GVHD-related mortality observed in
Batf3-/- mice upon HSCT.
CD8aþ DCs Suppress Allogeneic T Cell Responses by the
Induction of Treg Cells
Because CD8aþ DCs can induce FoxP3þ Treg cells in the
presence of TGF-b [32], we hypothesized that this might also
be a relevant mechanism in the context of allogeneic HSCT
because Treg cells arewell known for their ability to suppressFigure 5. Splenic Treg cells and serum levels of TGF-b are decreased in the absence o
(11 Gy in split dose) and transplanted allogeneic T celledepleted bone marrow cells
described before. (A) Splenocytes were harvested at day 7 post-HSCT and stained f
CD90.2þCD4- cells), and Treg cells (identiﬁed by propidium iodide CD3þ CD4þ FoxP3
SD) was determined using calibrated counting beads. (B) Serum samples were collect
depicted results are pooled from 2 independent experiments (n ¼ 6 per group). *St
difference by Student’s t-test (P > .05).GVHD [33]. First, we analyzed the number of donor T cell
recovery in spleen and the CD4/CD8 T cell ratio to charac-
terize the T cell response post-HSCT. Although the absolute
number of donor T cells appeared lower in Batf3-/- compared
with wild-type B6 hosts, there was no signiﬁcant difference
in the number of CD90þ T cells, suggesting a comparable
T cell recovery in Batf3-/- and wild-type B6 in the spleen
(Figure 5A, left). Likewise, we observed low CD4/CD8 ratios
indicative of CD8 skewed T cell responses without any sig-
niﬁcant differences in Batf3-/- or wild-type B6 hosts
(Figure 5A, middle). All donor T cells had an activated
phenotype (positive for CD25, not shown) compatible with a
strong allogeneic effector T cell response in GVHD. Notably,
we found a signiﬁcantly lower number of CD4þCD25þFoxP3þf CD8aþ DCs after HSCT. Recipient mice (B6 or Batf3-/-) were lethally irradiated
(5  106 cells) and CD90.2þ T cells (5  105 cells) from BALB/c donor mice as
or viable donor-derived H2-Kb CD90.2 T cells, CD4/CD8 ratio (CD90.2þCD4þ/
þ cells), respectively. The absolute number of T cells and Treg cells (mean and
ed and analyzed for IL-2 and TGF-b concentrations (mean þ SD) by ELISA. The
atistical signiﬁcance (P < .05) by Student’s t-test. n. s. indicates no signiﬁcant
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wild-type B6 controls after allogeneic HSCT (Figure 5A,
right). In addition, we analyzed sera of these transplanted
animals for IL-2 to further characterize the T cell response
und TGF-b, becasue induction of Treg cells by CD8aþ DCs can
be driven by TGF-b [32]. IL-2 levels were strongly elevated
(Figure 5B, left), whereas TGF-b levels were clearly reduced
in the transplanted Batf3-/- hosts compared with the wild-
type B6 controls (Figure 5B, right). Taken together, these
results suggest that Batf3-/- mice experience an aggravated
course of GVHD accompanied by increased IL-2 release
suggestive of an enhanced activation of allogeneic T cells and
reduced TGF-b levels, possibly related to the induction of
Treg cells by CD8aþ DCs.
DISCUSSION
Although nonhematopoietic cells can induce GVHD [8],
host-derived hematopoietic APCs have been shown to be the
essential for the induction of GVHD [3,34]. Although host-
derived DCs are sufﬁcient to mediate GHVD [6], we used 2
models of conventional DC depletion to clearly show that
host-derived CD11cþ DCs are not necessary, which is well in
line with a previous report by Li et al. [11]. Although they had
to use bone marrow chimeras of CD11c-DTR mice for HSCT
[35] because repeated diphtheria toxin treatments are lethal
in these animals due to promiscuous expression of the
transgene [36], this problem does not occur in the CD11c-
iDTR strain we used [22]. Therefore, our results are impor-
tant because they add a distinct model system (CD11c-iDTR
strain) and independently conﬁrm the previous data [11].
From our own previous work, where we have extensively
characterized the residual DCs in the CD11c-iDTR and CD11c-
DTA strains, we know that less than 5% of the normal DC
numbers are left in the host [22]. Therefore, we cannot
formally exclude that these remaining DCs are sufﬁcient to
induce GVHD. However, this degree of DC depletion is suf-
ﬁcient to ablate immune responses in other models
[21,35,37].
Although it remains controversial to what extent DCs are
required for the induction of GVHD, our results allow the
conclusion that host-derived DCs contribute to the amelio-
ration of GVHD, raising the question what DC subpopulation
is involved. Toubai et al. [16] previously demonstrated that
the vaccinationwith host-type CD8aþ DCs suppresses GVHD.
Hence, a suppressive effect of this DC subset on the course of
GVHD can be anticipated. Consistent with this notion, we
observed an aggravated course of GVHD in Batf3-/- mice
where CD8aþ DCs are lacking because the development of
CD8aþ DCs depends on the AP1 transcription factor Batf3
[14]. Our results nicely complement previous observations
by Teshima [38] detecting an expansion of CD8aþ DCs and a
decrease of GVHD-related mortality upon treatment of the
HSCT recipient with Flt3 ligand. The augmented GVHD-
related mortality in Batf3-/- mice and the enhanced MLR
using Batf3-/- APCs as stimulators are also compatible with an
enhanced allogeneic T cell priming induced by more acti-
vated residual DCs in the absence of CD8aþ DCs [39]. This
supports our ex vivo data showing increased levels of Ifng
mRNA in the DCs from the MLNs on day 2 and increased IL-2
levels in the serum on day 7 post-HSCT in Batf3-/- recipients
compared with the wild-type controls. Notably, we were
unable to detect any signiﬁcant differences in the recovery of
donor T cells or CD4/CD8 ratios post-HSCT of Batf3-/- or wild-
type recipients (Figure 5A). However, this may still be
compatible with the enhanced activation of allogeneic T cellsin Batf3-/- recipients because most effector cells may have
been recruited to GVHD target organs (ie, gut and liver) as
suggested by our histopathology ﬁndings (Figure 1D). Inter-
estingly, we found signiﬁcantly increased histopathology
signs of GVHD in the gut as opposed to the skin where the
signs of GVHD were diminished. Although we did not follow
up on this observation, this can be suspected to be related to
differences in the distribution of CD8aþ DCs and the related
nonlymphoid CD103þ DCs in the intestine versus the skin
[40,41].
As shown in Figure 2, host DCs were rapidly depleted
after TBI, leaving only a narrow time frame of 3 to 4 days for
priming of allogeneic T cells, which is in line with previous
reports [13,30]. Regarding the role of CD8aþ DCs in the
priming phase of GVHD, our data obtained with Batf3-/- hosts
suggest suppressive effects. Although Batf3-/- mice on B6
background are devoid of CD8aþ DCs under steady state,
they may acquire CD8aþ DCs under inﬂammatory conditions
after 3 to 14 days depending on the infectionmodel [18]. This
is mediated by compensatory mechanisms via Batf. There-
fore, it needs to be considered for our data that CD8aþ DCs
may be induced in Batf3-/- hosts upon TBI that we were un-
able to detect. However, given the rapid depletion of host
DCs after lethal TBI (Figure 2) and the enhanced GVHD-
related mortality in Batf3-/- hosts (Figure 1), these Batf-
dependent mechanisms are apparently insufﬁcient to fully
compensate the primary lack of CD8aþ DCs in Batf3-/- hosts.
Therefore, our results allow the conclusion that host CD8aþ
DCs are important counter-regulators in the initiation phase
of GVHD.
In contrast to our results, a study using a murine miHA
mismatch model showed no role for Batf3-dependent CD8aþ
DCs in GVHD induction but a requirement of this cell popu-
lation to induce an optimal GVT reaction [17]. However, an
obvious difference to our study is the MHC-matched HSCT
model and the use of puriﬁed CD8þ T cells in the graft, where
the ability of CD8aþ DC for the cross-presentation of tumor-
related miHA is clearly important. It appears unlikely that a
lack of cross-presentation of miHA can explain this differ-
ence, because miHA are ubiquitously and directly presented
by all host APCs in contrast to tumor antigens for the GVT
effect, which have to be taken up and presented by host
APCs. However, another major difference between both
models is that GVHD in the C3H.SW/B6 model is more
CD8þ T cell dependent, whereas our BALB/c/B6 model
mainly requires CD4þ T cells and CD8þ T cells to a lesser
extent [42]. Nevertheless, in the model of Toubai et al. [17] no
CD4þ T cells were transplanted, which may contribute to the
severity and kinetic of GVHD and explain the differences in
outcome. However, when considering the role of CD8aþ DCs
for GVT-speciﬁc CTL responses [17] in context of our results
demonstrating suppressive effects on priming of GVH-
speciﬁc T cell responses, it is tempting to speculate that
targeting of CD8aþ DCs may be important gate keepers to
separate GVH from GVT responses to concurrently improve
the efﬁcacy (GVT) and reduce toxicity (GVH) of HSCT.
Although clinical evidence in humans is currently missing,
the previous work by Teshima [38] using FLT3 ligand to
expand CD8aþ DCs in a similar MHC mismatched model of
GVHD (B6/B6D2F1) suggests a potential way to go.
The importance of the interaction of APCs with CD4þ
T cells is not only evident for priming of T cell responses in
the context of GVHD but also for the induction or mainte-
nance of tolerance, as Treg cells are of well-known signiﬁ-
cance in controlling GVHD by various mechanisms
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CD8aþ DCs can induce Treg cells in a TGF-b dependent
fashion [32,45]. Conversely, Treg cells preferentially make
contact with DCs inhibiting their activation, as previously
shown by us and others [46,47]. We detected a hyper-
activated DC phenotype after the TBI conditioning regimen
along with an enhanced MLR response in the absence of
CD8aþ DCs (Figure 4B). Because of the low recovery of DCs
from the MLNs post-TBI, we unable to directly perform the
MLRs with ex vivo puriﬁed DCs. Therefore, our experimental
setup does not allow to discriminate whether the enhanced
alloreactivity is mediated by CD8aþDCs in a direct or indirect
fashion.
The enhanced DC and Tcell activation in Batf3-/- hosts was
accompanied by a reduced number of Treg cells and
decreased TGF-b levels post-HSCT, suggesting the aggravated
course of GVHD observed in Batf3-/- mice is related by a
diminished induction of Treg cellemediated tolerance lead-
ing to enhanced Tcell priming and the exacerbation of GVHD,
although we did not provide a direct evidence for this in our
study. However, a similar mechanism involving Batf3-
dependent DCs mediated via PD-1 is in place for tolerance
induction in the kidney [48]. Likewise, PD-1 is necessary for
the DC-mediated induction of Treg cells in a model of
experimental autoimmune encephalitis [22]. Although the
PD-1/PD-L1 interaction in general is also highly important
for GVHD [49], we detected an increased expression of PD-L1
and PD-L2 on DCs from wild-type as well as Batf3-/- mice
post-TBI, suggesting these inhibitory B7 molecules are not
the key regulators of allogeneic T cell priming in this context.
Taken together, we conﬁrmed that conventional DCs are
not required for the induction of acute GVHD but also
demonstrated an important role of host-derived CD8aþ DCs
in counter-regulating the early inﬂammatory response after
HSCT. This is relevant for the severity and mortality of acute
GVHD. Our results enhance our current understanding of
how GVHD is initiated and may provide the basis for novel
concepts for an improved control of GVHD and better feasi-
bility of HSCT in the future.ACKNOWLEDGMENTS
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